Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Share-based Compensation (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Share-based Compensation data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 9.75% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $10.4 million, down 12.56%, while the annual FY2025 figure was $10.4 million, 12.56% down from the prior year.
  • Share-based Compensation reached $2.2 million in Q4 2025 per FHTX's latest filing, down from $2.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.6 million in Q1 2023 and bottomed at $1.9 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $3.1 million, with a median of $3.0 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 317.59% in 2021, then fell 29.48% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $2.1 million in 2021, then skyrocketed by 81.43% to $3.8 million in 2022, then decreased by 19.31% to $3.1 million in 2023, then decreased by 18.62% to $2.5 million in 2024, then decreased by 9.75% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.2 million in Q4 2025, $2.7 million in Q3 2025, and $2.7 million in Q2 2025.